DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022

Rhea-AI Summary

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced participation in one-on-one meetings at the upcoming BTIG Biotechnology Conference on August 8-9, 2022, held at the St. Regis New York Hotel and virtually. The company focuses on developing treatments for neurological and kidney diseases, with its lead candidate DM199 being a recombinant form of the human tissue kallikrein-1 protein. Interested attendees can schedule meetings through their BTIG representatives. For further information, visit www.diamedica.com.

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company’s management team will be participating in one-on-one meetings at the upcoming BTIG Biotechnology Conference, which is taking place both virtually and at the St. Regis New York Hotel in New York City, August 8-9, 2022.

For those interested in meeting with DiaMedica at the conference, please reach out to your BTIG representative to schedule a meeting.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant form of the human tissue kallikrein-1 protein (KLK1), an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit our website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005734/en/

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

Paul Papi

Corporate Communications

Phone: 617-899-5941

ppapi@diamedica.com

Source: DiaMedica Therapeutics Inc.

FAQ

When is DiaMedica Therapeutics participating in the BTIG Biotechnology Conference?

DiaMedica Therapeutics is participating in the BTIG Biotechnology Conference on August 8-9, 2022.

Where is the BTIG Biotechnology Conference being held?

The BTIG Biotechnology Conference is being held at the St. Regis New York Hotel and virtually.

What is DiaMedica Therapeutics' lead candidate?

DiaMedica's lead candidate is DM199, a recombinant form of the human tissue kallikrein-1 protein.

What diseases does DiaMedica Therapeutics focus on?

DiaMedica Therapeutics focuses on developing treatments for neurological disorders and kidney diseases.

How can one schedule a meeting with DiaMedica at the conference?

Interested parties can reach out to their BTIG representative to schedule a meeting with DiaMedica.